Burkitt lymphoma after solid-organ transplant: Treatment and outcomes in the paediatric PTLD collaborative.

Autor: Afify Z; Pediatric Hematology Oncology, Primary Children's Med. Ctr, Salt Lake City, Utah, USA., Orjuela-Grimm M; Division of Pediatric Hematology Oncology and Stem Cell Transplantation, and Department of Epidemiology, Columbia University Medical Center, New York, New York City, USA., Smith CM; Vanderbilt University Medical Center, Nashville, Tennessee, USA., Dalal M; University of Florida, Gainesville, Florida, USA., Ford JB; University of Nebraska Medical Center, Omaha, Nebraska, USA., Pillai P; Mount Sinai Kravis Children's Hospital, New York, New York City, USA., Robles JM; Department of Pediatrics, Division of Hematology/Oncology, Duke University School of Medicine, Durham, North Carolina, USA., Reddy S; Division of Pediatric Hematology Oncology and Stem Cell Transplantation, and Department of Epidemiology, Columbia University Medical Center, New York, New York City, USA., McCormack S; Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical center, Cincinnati, Ohio, USA.; Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA., Ehrhardt MJ; Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA., Ureda T; Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA., Alperstein W; Sylvester Comprehensive Cancer Center, Miller School of Medicine, University of Miami, Miami, Florida, USA., Edington H; Children's Healthcare of Atlanta, Emory University School of Medicine, Atlanta, Georgia, USA., Miller TP; Children's Healthcare of Atlanta, Emory University School of Medicine, Atlanta, Georgia, USA., Rubinstein JD; Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical center, Cincinnati, Ohio, USA.; Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA., Kavanaugh M; UPMC Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, USA., Bukowinski AJ; Department of Pediatrics, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA., Friehling E; Department of Pediatrics, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA., Rivers JM; Department of Pediatrics, Seattle Children's Hospital, Seattle, Washington, USA., Chisholm KM; Department of Laboratories, Seattle Children's Hospital, Seattle, Washington, USA., Marks LJ; Department of Pediatrics, Division of Pediatric Hematology and Oncology, Stanford University School of Medicine, Palo Alto, California, USA., Mason CC; Department of Pediatrics, Division of Pediatric Hematology and Oncology, University of Utah, Salt Lake City, Utah, USA.
Jazyk: angličtina
Zdroj: British journal of haematology [Br J Haematol] 2023 Feb; Vol. 200 (3), pp. 297-305. Date of Electronic Publication: 2022 Dec 01.
DOI: 10.1111/bjh.18498
Abstrakt: Burkitt lymphoma arising in paediatric post-solid-organ transplantation-Burkitt lymphoma (PSOT-BL) is a clinically aggressive malignancy and a rare form of post-transplant lymphoproliferative disorder (PTLD). We evaluated 35 patients diagnosed with PSOT-BL at 14 paediatric medical centres in the United States. Median age at organ transplantation was 2.0 years (range: 0.1-14) and age at PSOT-BL diagnosis was 8.0 years (range: 1-17). All but one patient had late onset of PSOT-BL (≥2 years post-transplant), with a median interval from transplant to PSOT-BL diagnosis of 4.0 years (range: 0.4-12). Heart (n = 18 [51.4%]) and liver (n = 13 [37.1%]) were the most frequently transplanted organs. No patients had loss of graft or treatment-related mortality. A variety of treatment regimens were used, led by intensive Burkitt lymphoma-specific French-American-British/Lymphomes Malins B (FAB/LMB), n = 13 (37.1%), and a low-intensity regimen consisting of cyclophosphamide, prednisone and rituximab (CPR) n = 12 (34.3%). Median follow-up was 6.7 years (range: 0.5-17). Three-year event-free and overall survival were 66.2% and 88.0%, respectively. Outcomes of PSOT-BL patients receiving BL-specific intensive regimens are comparable to reported BL outcomes in immunocompetent children. Multi-institutional collaboration is feasible and provides the basis of prospective data collection to determine the optimal treatment regimen for PSOT-BL.
(© 2022 British Society for Haematology and John Wiley & Sons Ltd.)
Databáze: MEDLINE
Externí odkaz: